Equity Profile

RGC

Regencell Bioscience Holdings Limited

Health CarePharmaceuticals$2.5B

Jun27Thu

Pre-Earnings Brief

UpcomingQ4-2017After Close5:00 PM EDT

Company Snapshot

Regencell Bioscience Holdings Limited operates in the health care sector, focusing on pharmaceuticals. The company is involved in developing innovative treatments, which could play a significant role in addressing unmet medical needs in the market.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RGC Q4-2017 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-3.97%

Avg Stock Reaction

+0.00%

Last Quarter Recap

In the last quarter, Regencell reported an EPS of $0.07, missing estimates by 36%. The company did not provide revenue figures, leaving investors uncertain about its performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Regencell's upcoming earnings are mixed due to previous misses and lack of guidance. Investors are cautious as they await clarity on the company's financial health.

Bull Case

If Regencell can demonstrate improved EPS and revenue growth, it may signal a turnaround and boost investor confidence.

Bear Case

Conversely, continued misses on EPS and revenue could lead to further declines in stock value and investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter?

The EPS figure will be crucial in determining if the company is on a path to recovery or if it continues to struggle.

How much has R&D spending increased compared to last quarter?

Increased R&D spending could indicate a commitment to innovation and future growth, which is vital for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Regencell to rebound given its recent investments in R&D, which could lead to improved product offerings.

Supporting Evidence

Despite recent misses, the company has a history of surprising positively when it invests heavily in R&D.

Options pricing suggests a significant move, indicating that market sentiment is more volatile than the consensus view.

Key Risk

If R&D spending shows a significant increase, it could shift investor sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The upcoming earnings report is critical as it will reveal whether Regencell can overcome its recent performance challenges.

Bull Confirmed If

An EPS of $0.15 or higher would confirm a positive outlook for the company.

Bear Confirmed If

An EPS below $0.05 would reinforce concerns about the company's financial stability.

Pre-Earnings Positioning

Options Market

Implied Move

±11.9%

The options market is pricing in a significant potential move, indicating uncertainty about the earnings report.

Detail

ATM IV

1.4%

30d HV

69.6%

Calls (5K)P/C Ratio: 0.02Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Regencell beats expectations, history suggests a positive reaction, potentially leading to a stock increase of around 3.6%.

In-Line / Cautious

If results are in line but cautious commentary is provided, the stock may experience minimal movement as investors reassess their outlook.

Miss

A miss on earnings could lead to a decline in stock value, with historical patterns suggesting a drop of around 1.3%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments and their expected timelines.
2Details on cost management strategies and their impact on profitability.
3Insights into market demand for Regencell's products.
4Clarification on the company's long-term growth strategy.
5Responses to analyst questions regarding past performance and future expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jun25

SNXReported

TD SYNNEX Corporation

RecapView

Jun25

CUKReported

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

N/A

Revenue Growth

Revenue growth is essential for assessing the company's ability to expand its market presence and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RGC Q4-2017 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-3.97%

Avg Stock Reaction

+0.00%

Last Quarter Recap

In the last quarter, Regencell reported an EPS of $0.07, missing estimates by 36%. The company did not provide revenue figures, leaving investors uncertain about its performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Regencell's upcoming earnings are mixed due to previous misses and lack of guidance. Investors are cautious as they await clarity on the company's financial health.

Bull Case

If Regencell can demonstrate improved EPS and revenue growth, it may signal a turnaround and boost investor confidence.

Bear Case

Conversely, continued misses on EPS and revenue could lead to further declines in stock value and investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter?

The EPS figure will be crucial in determining if the company is on a path to recovery or if it continues to struggle.

How much has R&D spending increased compared to last quarter?

Increased R&D spending could indicate a commitment to innovation and future growth, which is vital for investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Regencell to rebound given its recent investments in R&D, which could lead to improved product offerings.

Supporting Evidence

Despite recent misses, the company has a history of surprising positively when it invests heavily in R&D.

Options pricing suggests a significant move, indicating that market sentiment is more volatile than the consensus view.

Key Risk

If R&D spending shows a significant increase, it could shift investor sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The upcoming earnings report is critical as it will reveal whether Regencell can overcome its recent performance challenges.

Bull Confirmed If

An EPS of $0.15 or higher would confirm a positive outlook for the company.

Bear Confirmed If

An EPS below $0.05 would reinforce concerns about the company's financial stability.

Pre-Earnings Positioning

Options Market

Implied Move

±11.9%

The options market is pricing in a significant potential move, indicating uncertainty about the earnings report.

Detail

ATM IV

1.4%

30d HV

69.6%

Calls (5K)P/C Ratio: 0.02Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Regencell beats expectations, history suggests a positive reaction, potentially leading to a stock increase of around 3.6%.

In-Line / Cautious

If results are in line but cautious commentary is provided, the stock may experience minimal movement as investors reassess their outlook.

Miss

A miss on earnings could lead to a decline in stock value, with historical patterns suggesting a drop of around 1.3%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments and their expected timelines.
2Details on cost management strategies and their impact on profitability.
3Insights into market demand for Regencell's products.
4Clarification on the company's long-term growth strategy.
5Responses to analyst questions regarding past performance and future expectations.